Table 1.

Patient characteristics when starting hepatitis C (HCV) treatment with daclatasvir (n = 249)

Characteristics	All	Genotype			Ribavirin
		1a	3b	Otherc	With	Without
	n = 249	n = 187	n = 40	n = 22	n = 66	n = 183
Age, median (years)	56	56	55	55	55	57
Male (%)	78	75	85	91	85	76
HIV co-infection (%)	10	8	15	14	11	9
Prior HCV treatment (%)	65	69	48	64	65	65
Cirrhosis (%)
- No	14	16	5	14	18	13
- Compensated	27	21	48	36	27	26
- Decompensated	59	63	48	50	55	61
Child Pugh class (%)
- A	27	27	20	41	29	26
- B	33	37	23	14	33	32
- C	8	9	3	9	5	9
- Unknown	33	27	55	36	33	32
Fibrosis stage (%)
- < F3	9	9	5	14	9	9
- F3 – F4	82	83	73	82	82	81
- Unknown	10	8	23	5	9	10
Hepatocellular carcinoma (%)
- Never	58	56	65	68	61	57
- Past	17	19	13	14	18	17
- Current	12	13	10	9	15	12
- Unknown	12	12	13	9	6	14
Liver transplantation (%)
- Never	34	31	50	32	27	36
- On list	13	14	13	9	11	14
- Before current treatment	40	40	33	50	44	38
- During current treatment	11	13	3	9	12	10
- Unknown	2	3	3	0	6	1

^aGenotypes 1 (n = 14), 1a (n = 58), 1a/b (n = 3), and 1b (n = 112)

^bGenotypes 3 (n = 18), 3a (n = 21) and 3 h (n = 1)

^cGenotypes 2 (n = 4), 4 (n = 17) and 5 (n = 1)